Nexus Finance
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF | IE00BYXG2H39

TER

0.35%

Total Expense Ratio per year

Fund Size

$1168697.26B

Assets under management

Holdings

251

Underlying equities

Dividend Yield

0.00%

Accumulating

Performance Analysis

Based on selected timeframe (1D)

Top Performers - Upside

Oric Pharmaceuticals, Inc. ORIC
+11.11%
LENZ Therapeutics, Inc. LENZ
+8.51%
Silence Therapeutics PLC R XRP2.F
+8.11%

Top Performers - Downside

Codexis, Inc. CDXS
-25.63%
Zevra Therapeutics, Inc. ZVRA
-23.92%
Jyong Biotech Ltd. MENS
-12.92%

Top Contributors - Upside

Amgen Inc. AMGN • Weight: 7.61% • Perf: +1.22%
+0.09% Impact
Vertex Pharmaceuticals Incorpor VRTX • Weight: 7.82% • Perf: +0.90%
+0.07% Impact
Alnylam Pharmaceuticals, Inc. ALNY • Weight: 2.81% • Perf: +1.13%
+0.03% Impact

Top Contributors - Downside

Moderna, Inc. Weight: 2.04% • Perf: -5.17%
-0.11% Impact
Gilead Sciences, Inc. Weight: 7.07% • Perf: -1.18%
-0.08% Impact
Summit Therapeutics Inc. Weight: 0.81% • Perf: -8.81%
-0.07% Impact

ETF Profile

Provider iShares
Region N/A
Country US
Sector Health Care
Strategy N/A
Theme Biotech
Distribution Policy Accumulating
Replication Optimized sampling
Sustainable No

Aggregate Fundamentals

Weighted average of underlying holdings

Avg P/E Ratio 23.60
Avg Forward P/E 58.18

Growth Analysis

EPS Growth (LY->CY) -272.96%
Revenue Growth (LY->CY) +61.81%
EPS Growth (CY->NY) +137.72%
Revenue Growth (CY->NY) +363.75%
ende